GO:0045988 negative regulation of striated muscle contraction: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045988 describes any process that stops, prevents, or reduces the frequency, rate or extent of striated muscle contraction, a biological_process annotation in the Gene Ontology.
• Striated muscle contraction is driven by calcium-dependent actin-myosin cycling, and its negative regulation is essential for diastolic relaxation, energy conservation, and protection from hypercontractile injury.
• Key molecular brakes include troponin I (TNNI1/TNNI2/TNNI3), troponin C isoforms, myosin-binding protein C (MYBPC3), and calcium-handling proteins such as SERCA (ATP2A2) and phospholamban (PLN).
• Post-translational modifications, including acetylation by p300/CBP and phosphorylation by kinases, tune contractile output and can enforce negative regulation.
• Dysregulation of negative regulation underlies hypertrophic cardiomyopathy, skeletal myopathies, and muscle atrophy, making this term central to translational muscle research.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of negative regulators in striated muscle.
Description
GO:0045988, negative regulation of striated muscle contraction, is a Gene Ontology biological_process term that captures any process which stops, prevents, or reduces the frequency, rate or extent of striated muscle contraction. Striated muscle, comprising cardiac and skeletal muscle, contracts through calcium-dependent interactions between actin and myosin, and this activity must be tightly restrained to permit relaxation, match energy supply to demand, and avoid pathological hypercontractility. The term therefore encompasses molecular brakes such as inhibitory troponin isoforms, calcium reuptake mechanisms, and signaling pathways that dampen sarcomeric activity. For researchers, GO:0045988 provides a standardized framework to annotate genes and pathways that suppress contraction. Mutations or expression changes in negative regulators are linked to hypertrophic cardiomyopathy, skeletal muscle pathologies, and atrophy, underscoring the clinical relevance of this process. Understanding how contraction is negatively regulated also informs exercise physiology, circadian muscle biology, and regenerative medicine. This article integrates the QuickGO definition with verified PubMed literature to outline the mechanisms, key genes, disease connections, and experimental strategies, including CRISPR-based models, for studying negative regulation of striated muscle contraction.
negative regulation of striated muscle contraction At A Glance
| GO ID | GO:0045988 |
|---|---|
| GO term | negative regulation of striated muscle contraction |
| Ontology | biological_process |
| Synonym | down regulation of striated muscle contraction; down-regulation of striated muscle contraction; downregulation of striated muscle contraction; inhibition of striated muscle contraction |
| Major function | Stops, prevents, or reduces the frequency, rate or extent of striated muscle contraction |
| Related processes | Regulation of muscle contraction, calcium ion transport, sarcomere organization, relaxation |
| Cellular context | Cardiomyocytes and skeletal muscle fibers |
| Disease relevance | Hypertrophic cardiomyopathy, skeletal myopathies, muscle atrophy |
What Is GO:0045988?
In plain terms, GO:0045988 describes the biological processes that put the brakes on striated muscle contraction. According to the Gene Ontology, it is any process that stops, prevents, or reduces the frequency, rate or extent of striated muscle contraction. This includes molecular events that inhibit calcium signaling, sarcomeric cycling, or the signaling cascades that initiate contraction, thereby promoting relaxation or preventing excessive contraction.
Why Is negative regulation of striated muscle contraction Important in Cell Biology?
Negative regulation of striated muscle contraction is essential for normal physiology because it allows the heart to relax and refill between beats and permits skeletal muscle to conserve energy and avoid damage from sustained contraction. Disruption of these braking mechanisms can cause hypercontractile states, hypertrophic cardiomyopathy, and skeletal muscle disease, while excessive negative regulation contributes to atrophy and weakness. Thus, GO:0045988 is a focal point for understanding muscle disease mechanisms and for developing targeted therapies.
• Enables diastolic relaxation and cardiac filling by restraining contraction.
• Prevents energy depletion and hypercontractile injury in skeletal and cardiac muscle.
• Mutations in negative regulators such as MYBPC3 and TNNI3 cause hypertrophic cardiomyopathy.
• Dysregulation contributes to skeletal muscle pathologies and atrophy.
• Provides targets for therapeutic modulation of contractility in heart failure and myopathies.
• Integrates with circadian and metabolic signaling that tunes muscle performance.
• Post-translational modifications by p300/CBP alter contractile regulation.
• Supports regenerative processes by balancing contraction and maturation.
• Offers biomarkers such as troponins for muscle injury.
• Guides CRISPR-based functional genomics of muscle disease genes.
What Happens During negative regulation of striated muscle contraction?
Calcium-dependent inhibition of sarcomeric activation
In simple terms: Lowering calcium or blocking its sensor stops the muscle from contracting.
Striated muscle contraction is triggered when calcium binds troponin C, moving tropomyosin to expose myosin-binding sites on actin. Negative regulation can occur by reducing calcium availability or by altering troponin sensitivity. Inhibitory troponin I isoforms (TNNI1, TNNI2, TNNI3) bind actin-tropomyosin and block myosin ATPase activity, thereby preventing contraction. Calcium reuptake by SERCA (ATP2A2) and its inhibitor phospholamban (PLN) lowers cytosolic calcium and terminates contraction, a key negative regulatory step.
Sarcomeric braking by myosin-binding protein C and titin
In simple terms: Structural proteins in the sarcomere can act as molecular brakes.
MYBPC3 binds myosin and modulates cross-bridge cycling, acting as a brake that reduces contraction speed and force. Mutations in MYBPC3 are a common cause of hypertrophic cardiomyopathy, reflecting loss of negative regulation. Titin (TTN) contributes to passive tension and signaling that can limit contraction, and its isoforms are regulated during development and disease.
Post-translational tuning of contractile proteins
In simple terms: Chemical tags on contractile proteins can turn down contraction.
Acetylation by the acetyltransferases p300 and CBP regulates skeletal muscle contractile function, and their activity can alter myofilament sensitivity and force production. Phosphorylation of troponin and myosin regulatory light chains by kinases also modulates contraction, providing reversible negative regulation.
Signaling pathways that suppress contraction
In simple terms: Cellular signals can tell the muscle to relax or reduce force.
Beta-adrenergic signaling generally enhances contraction, but negative regulation can be mediated by phosphatases, nitric oxide signaling, and metabolic sensors. For example, the gut microbe-derived metabolite phenylacetylglutamine acts as an allosteric modulator of beta-2 adrenergic receptors, which can influence cardiac contractility. Circadian regulation also impacts muscle growth and function independent of locomotor activity, potentially affecting contractile regulation.
Developmental and regenerative control of contractility
In simple terms: During growth and repair, contraction is kept in check to allow proper maturation.
In cardiomyocyte maturation during regeneration, the interplay between calcium and sarcomeres directs maturation, and negative regulation ensures proper assembly before full contractile function. Muscle satellite cell dysfunction in neuromuscular disorders highlights how regenerative capacity is linked to contractile regulation.
Key Genes Involved in GO:0045988 negative regulation of striated muscle contraction
The following genes encode proteins that directly or indirectly mediate negative regulation of striated muscle contraction, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TNNI1 | Slow skeletal troponin I; inhibits actomyosin ATPase | Negative regulator in slow skeletal muscle |
| TNNI2 | Fast skeletal troponin I; inhibits contraction | Fast-twitch muscle regulation |
| TNNI3 | Cardiac troponin I; inhibits cardiac contraction | Mutations cause hypertrophic cardiomyopathy |
| TNNT2 | Cardiac troponin T; modulates calcium sensitivity | Mutations linked to cardiomyopathy |
| MYBPC3 | Myosin-binding protein C; brakes cross-bridge cycling | Common hypertrophic cardiomyopathy gene |
| MYH7 | Beta-myosin heavy chain; contractile protein | Mutations alter contractility |
| ATP2A2 | SERCA2 calcium pump; lowers cytosolic calcium | Terminates contraction, promotes relaxation |
| PLN | Phospholamban; inhibits SERCA | Regulates calcium reuptake |
| TTN | Titin; passive tension and signaling | Sarcomeric brake and sensor |
| EP300 | p300 acetyltransferase; modifies contractile proteins | Post-translational regulation of contraction |
| CREBBP | CBP acetyltransferase; modifies contractile proteins | Post-translational regulation of contraction |
| ADRB2 | Beta-2 adrenergic receptor; modulated by metabolites | Allosteric modulation of contractility |
| MTOR | mTOR kinase; integrates nutrient and contraction signals | Muscle growth and contractile adaptation |
| PER1 | Circadian clock protein; regulates muscle growth | Circadian control of muscle function |
| PER2 | Circadian clock protein; regulates muscle growth | Circadian control of muscle function |
| PAX7 | Satellite cell marker; regeneration | Satellite cell dysfunction in myopathies |
| MYOD1 | Myogenic differentiation factor | Muscle regeneration and repair |
| MEF2C | Transcription factor; muscle gene expression | Regulates contractile gene programs |
How Is negative regulation of striated muscle contraction Regulated?
Negative regulation of striated muscle contraction is itself regulated at multiple levels. Calcium handling by SERCA and phospholamban is modulated by phosphorylation, and beta-adrenergic signaling can either enhance or dampen contraction depending on context. Post-translational acetylation by p300/CBP alters myofilament function and can enforce negative regulation. Circadian clock proteins such as PER1 and PER2 influence muscle growth and contractile properties independent of locomotor activity. Additionally, mTOR signaling integrates nutrient and contraction cues to control muscle protein synthesis and adaptation, indirectly affecting contractile capacity.
negative regulation of striated muscle contraction and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MYBPC3 | Hypertrophic cardiomyopathy | Knock-in mouse or iPSC-derived cardiomyocytes with patient mutation |
| TNNI3 | Hypertrophic cardiomyopathy, restrictive cardiomyopathy | Point-mutation knock-in in cardiomyocytes |
| ATP2A2 | Heart failure, Darier disease | Overexpression or knockout in cardiac cell lines |
| PLN | Cardiomyopathy, heart failure | Knockout and phosphomutant knock-in models |
| EP300 | Muscle atrophy, cancer | Conditional knockout in skeletal muscle |
Hypertrophic cardiomyopathy and sarcomeric mutations
Mutations in genes encoding negative regulators of contraction, such as MYBPC3 and TNNI3, are leading causes of hypertrophic cardiomyopathy. Loss of braking function leads to hypercontractility, sarcomere disarray, and cardiac hypertrophy. Troponin mutations can alter calcium sensitivity and impair relaxation, contributing to diastolic dysfunction.
Skeletal muscle pathologies and atrophy
Dysregulation of negative regulation contributes to skeletal muscle pathologies, including atrophy and myopathies. Physical exercise can counteract atrophy by modulating contractile and metabolic pathways. Muscle satellite cell dysfunction in neuromuscular disorders further impairs regeneration and contractile recovery.
Metabolic and circadian influences on muscle disease
Circadian disruption alters muscle growth and contractile function, potentially exacerbating metabolic muscle disease. The gut microbe-derived metabolite phenylacetylglutamine modulates beta-2 adrenergic receptors, linking microbiome metabolism to cardiac contractility and disease.
From negative regulation of striated muscle contraction-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of MYBPC3 increase contractility? | MYBPC3 knockout cardiomyocytes |
| Does a TNNI3 mutation alter calcium sensitivity? | TNNI3 point-mutation knock-in iPSC-cardiomyocytes |
| Can SERCA overexpression improve relaxation? | ATP2A2 overexpression in cardiac cells |
| Is p300 required for contractile gene regulation? | EP300 knockout skeletal muscle cells |
| Does circadian clock regulate contraction? | PER1/PER2 knockout muscle models |
| Can satellite cell dysfunction be rescued? | PAX7 knock-in reporter mice |
How to Study the negative regulation of striated muscle contraction Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Calcium imaging | Cytosolic calcium transients | Assess relaxation and SERCA function |
| Sarcomere shortening | Contractile force and kinetics | Measure negative regulation in cardiomyocytes |
| RNA-seq | Transcript abundance | Identify expression changes in muscle disease |
| Proteomics | Protein levels and modifications | Map acetylation of contractile proteins |
| CRISPR knockout screen | Gene essentiality for contractility | Discover negative regulators |
| Western blot | Protein phosphorylation | Measure signaling changes |
| Exercise testing | Muscle performance | Evaluate atrophy interventions |
Calcium imaging and contractility assays
Calcium transients and sarcomere shortening can be measured in isolated cardiomyocytes or myotubes using fluorescent dyes and edge-detection systems. These assays directly quantify negative regulation by assessing relaxation kinetics and calcium reuptake.
Transcriptomics and proteomics
RNA-seq and proteomics identify expression changes in negative regulators such as TNNI isoforms, MYBPC3, and ATP2A2 under disease or exercise conditions. Post-translational modifications can be mapped by mass spectrometry.
CRISPR screens and functional genomics
Pooled CRISPR knockout screens in muscle cell lines can identify genes whose loss alters contractility or calcium handling, revealing novel negative regulators.
In vivo physiology and exercise models
Treadmill or voluntary wheel running in mice assesses muscle function and adaptation, while circadian studies require time-of-day controlled experiments.
How CRISPR Can Be Used to Study GO:0045988 negative regulation of striated muscle contraction
Knockout
CRISPR knockout of candidate negative regulators such as MYBPC3 or TNNI3 in cardiomyocytes or skeletal muscle cells can test whether loss of function increases contraction. This approach is validated in studies of muscle satellite cell dysfunction and contractile regulation.
Point Mutation
Introducing disease-associated point mutations (e.g., in TNNI3 or MYBPC3) via CRISPR base editing or HDR allows precise modeling of altered contractility and calcium sensitivity, as seen in hypertrophic cardiomyopathy research.
Knock-in
Knock-in of reporter tags or patient mutations into endogenous loci enables tracking of protein localization and function in live muscle cells, facilitating studies of sarcomeric braking.
Overexpression
CRISPR activation or cDNA overexpression of negative regulators like ATP2A2 or PLN can enhance relaxation and rescue hypercontractile phenotypes, providing therapeutic proof-of-concept.
How EDITGENE Supports negative regulation of striated muscle contraction Research
Researchers studying negative regulation of striated muscle contraction-related genes often need to determine whether a candidate gene is causally involved in suppressing contractility or whether its modulation can rescue disease phenotypes. EDITGENE provides end-to-end CRISPR services to generate precisely engineered muscle cell models for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of striated muscle contraction research.
Frequently Asked Questions About negative regulation of striated muscle contraction
What is GO:0045988?
GO:0045988 is the Gene Ontology term for negative regulation of striated muscle contraction, defined as any process that stops, prevents, or reduces the frequency, rate or extent of striated muscle contraction.
What genes are involved in negative regulation of striated muscle contraction?
Key genes include TNNI1, TNNI2, TNNI3, MYBPC3, ATP2A2, PLN, and TTN, which act as molecular brakes on contraction.
How does calcium regulate striated muscle contraction?
Calcium binding to troponin C triggers contraction, while calcium reuptake by SERCA (ATP2A2) and inhibition by phospholamban terminate contraction, contributing to negative regulation.
What diseases are linked to defective negative regulation of contraction?
Hypertrophic cardiomyopathy, skeletal myopathies, and muscle atrophy are linked to defects in negative regulators such as MYBPC3 and TNNI3.
How can CRISPR be used to study negative regulation of striated muscle contraction?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of candidate genes in muscle cells.
What is the role of MYBPC3 in muscle contraction?
MYBPC3 binds myosin and acts as a brake on cross-bridge cycling; mutations cause hypertrophic cardiomyopathy.
How does p300/CBP regulate muscle contractile function?
p300 and CBP acetyltransferases post-translationally modify contractile proteins, tuning force production and negative regulation.
Can exercise affect negative regulation of contraction?
Physical exercise modulates muscle atrophy and contractile function, partly by altering expression of regulatory proteins.
What is the role of circadian clock in muscle contraction?
Circadian proteins PER1 and PER2 regulate muscle growth and function independent of locomotor activity, influencing contractile regulation.
How does the gut microbiome influence cardiac contractility?
The microbial metabolite phenylacetylglutamine acts as an allosteric modulator of beta-2 adrenergic receptors, affecting cardiac contractility.
Conclusion
GO:0045988, negative regulation of striated muscle contraction, is a critical biological process that restrains contractile activity through calcium handling, sarcomeric braking, and post-translational modifications. Its dysregulation is central to hypertrophic cardiomyopathy, skeletal myopathies, and atrophy, making it a high-value target for research and therapeutic development. By leveraging CRISPR knockout, point-mutation, knock-in, and overexpression models, researchers can causally dissect these regulatory mechanisms. EDITGENE offers comprehensive services to accelerate discovery in this field.
References
- 1. Ganassi M et al.. 2022. Involvement of muscle satellite cell dysfunction in neuromuscular disorders: Expanding the portfolio of satellite cell-opathies.. Eur J Transl Myol 32(1) PMID: 35302338
- 2. Mishima T et al.. 2025. Time-of-day effect of high-intensity muscle contraction on mTOR signaling and protein synthesis in mice.. Sci Rep 15(1):23702 PMID: 40610492
- 3. Bogomolova AP et al.. 2024. Troponins and Skeletal Muscle Pathologies.. Biochemistry (Mosc) 89(12):2083-2106 PMID: 39865025
- 4. Saha PP et al.. 2024. Gut microbe-generated phenylacetylglutamine is an endogenous allosteric modulator of β2-adrenergic receptors.. Nat Commun 15(1):6696 PMID: 39107277
- 5. Nguyen PD et al.. 2023. Interplay between calcium and sarcomeres directs cardiomyocyte maturation during regeneration.. Science 380(6646):758-764 PMID: 37200435
- 6. Kelu JJ et al.. 2020. Circadian regulation of muscle growth independent of locomotor activity.. Proc Natl Acad Sci U S A 117(49):31208-31218 PMID: 33229575
- 7. Meyer GA et al.. 2024. Insights into posttranslational regulation of skeletal muscle contractile function by the acetyltransferases, p300 and CBP.. J Appl Physiol (1985) 136(6):1559-1567 PMID: 38722753
- 8. Shen L et al.. 2018. Physical Exercise for Muscle Atrophy.. Adv Exp Med Biol 1088:529-545 PMID: 30390268
